Literature DB >> 11389036

Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia.

A A George1, J Franklin, K Kerkof, A J Shah, M Price, E Tsark, D Bockstoce, D Yao, N Hart, S Carcich, R Parkman, G M Crooks, K Weinberg.   

Abstract

Successful autologous hematopoietic stem cell (HSC) transplantation in childhood acute lymphoblastic leukemia (ALL) requires the ability to either selectively kill the leukemia cells or separate normal from leukemic HSC. Based on previous studies showing that more than 95% of childhood B-lineage ALL express CD38, this study evaluated whether normal CD34(+)CD38(-) progenitors from children with B-lineage ALL could be isolated by flow cytometry. CD34(+) cells from bone marrow samples from 10 children with B-lineage ALL were isolated at day 28 of treatment, when clinical remission had been attained. The CD34(+) progenitor cells were flow cytometrically sorted into CD34(+)CD38(+) and CD34(+)CD38(-) populations. The absolute numbers of CD34(+)CD38(-) cells that could be isolated ranged from 401 to 6245. The cells were then analyzed for the presence of clonotypic rearrangements of the T-cell receptor (TCR) Vdelta2-Ddelta3 locus. Only patients whose diagnostic marrow had an informative TCR Vdelta2-Ddelta3 rearrangement were included in this study. Detection thresholds were typically 10(-4) to 10(-5) leukemic cells in normal marrow. In 6 of 10 samples analyzed, the sorted CD34(+)CD38(-) cells had no detectable Vdelta2-Ddelta3 rearrangements. In 4 cases, the clonotypic leukemic Vdelta2-Ddelta3 rearrangement was detected in the CD34(+)CD38(-) population, indicating that the putative normal HSC population also contained leukemic cells. The data indicate that although most childhood ALL cells express CD34 and CD38, leukemic cells are also frequently present in the CD34(+)CD38(-) population. Therefore, strategies to isolate and transplant normal HSC from children with ALL will require a more stringent definition of the normal HSC than the CD34(+)CD38(-) phenotype. (Blood. 2001;97:3925-3930)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389036     DOI: 10.1182/blood.v97.12.3925

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  The paradox of response and survival in cancer therapeutics.

Authors:  Carol Ann Huff; William Matsui; B Douglas Smith; Richard J Jones
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

Review 2.  A primitive cell origin for B-cell precursor ALL?

Authors:  C V Cox; A Blair
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 3.  GPCRs in stem cell function.

Authors:  Van A Doze; Dianne M Perez
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

4.  Circulating clonotypic B cells in classic Hodgkin lymphoma.

Authors:  Richard J Jones; Christopher D Gocke; Yvette L Kasamon; Carole B Miller; Brandy Perkins; James P Barber; Milada S Vala; Jonathan M Gerber; Lan L Gellert; Mark Siedner; M Victor Lemas; Sarah Brennan; Richard F Ambinder; William Matsui
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

Review 5.  Cancer stem cells: controversies in multiple myeloma.

Authors:  Sarah K Brennan; William Matsui
Journal:  J Mol Med (Berl)       Date:  2009-09-17       Impact factor: 4.599

6.  Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.

Authors:  V Agnusdei; S Minuzzo; C Frasson; A Grassi; F Axelrod; S Satyal; A Gurney; T Hoey; E Seganfreddo; G Basso; S Valtorta; R M Moresco; A Amadori; S Indraccolo
Journal:  Leukemia       Date:  2013-06-18       Impact factor: 11.528

7.  Characterization of clonogenic multiple myeloma cells.

Authors:  William Matsui; Carol Ann Huff; Qiuju Wang; Matthew T Malehorn; James Barber; Yvette Tanhehco; B Douglas Smith; Curt I Civin; Richard J Jones
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

Review 8.  Leukemia stem cells and human acute lymphoblastic leukemia.

Authors:  Kathrin M Bernt; Scott A Armstrong
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

9.  Induction of acute lymphocytic leukemia differentiation by maintenance therapy.

Authors:  T L Lin; M S Vala; J P Barber; J E Karp; B D Smith; W Matsui; R J Jones
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

10.  The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.

Authors:  Pin-Yi Wang; Fay Young; Chun-Yu Chen; Brett M Stevens; Sarah J Neering; Randall M Rossi; Timothy Bushnell; Igor Kuzin; David Heinrich; Andrea Bottaro; Craig T Jordan
Journal:  Blood       Date:  2008-08-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.